Abstract
The endocannabinoids system (ECS) has garnered considerable interest as a potential therapeutic target in various carcinomas and cancer-related conditions alongside neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy-induced nausea and vomiting (CINV). However, pharmacokinetics and pharmacodynamics interactions could be perceived in drug combinations, so in this short review we tried to shed light on the potential drug interactions of medicinal cannabis. Hitherto, few data have been provided to the healthcare practitioners about the drug–drug interactions of cannabinoids with other prescription medications. In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters (Glycoprotein p, breast cancer resistance proteins, and multidrug resistance proteins) and metabolizing enzymes (Cytochrome P450 and UDP-glucuronosyltransferases). Caution should be undertaken to closely monitor the responses of cannabis users with certain drugs to guard their safety, especially for the elderly and people with chronic diseases or kidney and liver conditions.
Highlights
The Cannabis sativa L. has long been used in traditional medicines around the world for treating various conditions [1]
Caution should be undertaken to closely monitor the responses of cannabis users with certain drugs to guard their safety, especially for the elderly and people with chronic diseases or kidney and liver conditions
CBD can interact with other receptors such as peroxisome proliferator-activated receptors (PPARs), orphan G-protein coupled receptor (GPR55), and transient receptor potential channel subfamily V member 1 (TRPV1) [3,4]
Summary
The Cannabis sativa L. (cannabis) has long been used in traditional medicines around the world for treating various conditions [1]. A recent review scrutinised the preclinical and clinical preclinical clinical studies for the medical use of cannabis [8]. Studies ofStudies oral or oromucosal cannabinoid spray or pulmonary administration of cannabis in smoke in oncology patients showed its tolerability with dose-dependent adverse effects A cocktail of medications is usually given to cancer patients to to overcome resilient cancercomplexity, complexity,ininmost mostcases caseswith withcombinatorial combinatorial chemotherapeutic chemotherapeutic agents overcome resilient cancer agents alongside alleviating medications such as antiemetics, appetite stimulant pain killers. In alongside alleviating medications such as antiemetics, appetite stimulant and and pain In this this regard, minimize the chemotherapeutic agents regard, there there is is potential potential to to reduce reduce or or minimize the adverse adverse effects effects of of chemotherapeutic agents by by using natural products such as cannabinoids. The PubMed retrieved publications (1990–2018) for studies on medicinal cannabis/marijuana/cannabinoids/tetrahydrocannabinol/cannabidiol
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
